[go: up one dir, main page]

MA33244B1 - Composes de vinylindazolyle - Google Patents

Composes de vinylindazolyle

Info

Publication number
MA33244B1
MA33244B1 MA34312A MA34312A MA33244B1 MA 33244 B1 MA33244 B1 MA 33244B1 MA 34312 A MA34312 A MA 34312A MA 34312 A MA34312 A MA 34312A MA 33244 B1 MA33244 B1 MA 33244B1
Authority
MA
Morocco
Prior art keywords
vinylindazolyl
compounds
indazolyl
cancer
treatment
Prior art date
Application number
MA34312A
Other languages
English (en)
Inventor
Daohong Chen
Hong-Yu Li
Genshi Zhao
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA33244B1 publication Critical patent/MA33244B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention porte sur des composés vinyl indazolylés utiles dans le traitement du cancer.
MA34312A 2009-05-07 2010-05-04 Composes de vinylindazolyle MA33244B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17629009P 2009-05-07 2009-05-07
US30141610P 2010-02-04 2010-02-04
PCT/US2010/033487 WO2010129509A1 (fr) 2009-05-07 2010-05-04 Composés vinyl indazolylés

Publications (1)

Publication Number Publication Date
MA33244B1 true MA33244B1 (fr) 2012-05-02

Family

ID=42238704

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34312A MA33244B1 (fr) 2009-05-07 2010-05-04 Composes de vinylindazolyle

Country Status (34)

Country Link
US (1) US8268869B2 (fr)
EP (1) EP2427449B1 (fr)
JP (1) JP5555314B2 (fr)
KR (1) KR101373910B1 (fr)
CN (1) CN102421769B (fr)
AR (1) AR078411A1 (fr)
AU (1) AU2010246114B2 (fr)
BR (1) BRPI1013748A2 (fr)
CA (1) CA2760535C (fr)
CL (1) CL2011002781A1 (fr)
CO (1) CO6450624A2 (fr)
CR (1) CR20110580A (fr)
DK (1) DK2427449T3 (fr)
EA (1) EA018149B1 (fr)
EC (1) ECSP11011441A (fr)
ES (1) ES2408117T3 (fr)
HN (1) HN2011002809A (fr)
HR (1) HRP20130323T1 (fr)
IL (1) IL216004A (fr)
JO (1) JO2860B1 (fr)
MA (1) MA33244B1 (fr)
ME (1) ME01462B (fr)
MX (1) MX2011011342A (fr)
MY (1) MY160390A (fr)
NZ (1) NZ595553A (fr)
PE (2) PE20160124A1 (fr)
PL (1) PL2427449T3 (fr)
PT (1) PT2427449E (fr)
RS (1) RS52795B (fr)
SG (1) SG175909A1 (fr)
SI (1) SI2427449T1 (fr)
TW (1) TWI382982B (fr)
UA (1) UA104756C2 (fr)
WO (1) WO2010129509A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3062B1 (ar) * 2010-10-05 2017-03-15 Lilly Co Eli R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
HK1205528A1 (en) 2012-03-08 2015-12-18 Astellas Pharma Inc. Novel fgfr3 fusion product
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
US20150203589A1 (en) 2012-07-24 2015-07-23 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AU2014236947A1 (en) 2013-03-15 2015-09-03 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
JP6449244B2 (ja) 2013-04-19 2019-01-09 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ抑制剤としての二環式複素環
CN103819396B (zh) * 2014-02-26 2016-06-15 四川大学 一种手性的1-（3,5-二氯吡啶-4-基）-乙醇的合成方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016105517A1 (fr) 2014-12-23 2016-06-30 The Trustees Of Columbia University In The City Of New York Protéines de fusion et procédés associés
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
ES2751669T3 (es) 2015-02-20 2020-04-01 Incyte Corp Heterociclos bicíclicos como inhibidores FGFR
WO2016134294A1 (fr) 2015-02-20 2016-08-25 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN105906621A (zh) * 2015-04-06 2016-08-31 四川百利药业有限责任公司 用作fgfr抑制剂的乙醇类化合物
WO2016187767A1 (fr) * 2015-05-25 2016-12-01 Hutchison Medipharma Limited Compositions pharmaceutiques et utilisation de celles-ci
JP6898306B2 (ja) * 2015-08-07 2021-07-07 ハルビン チェンバオ ファーマシューティカル カンパニー リミテッド Ｆｇｆｒ及びｖｅｇｆｒ阻害剤であるビニル化合物
US10214515B2 (en) 2015-08-20 2019-02-26 Zhejiang Hisun Pharmaceutical Co., Ltd. Substituted pyrazoles as inhibitors of fibroblast growth factor receptor
CN107459519A (zh) 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
PE20210919A1 (es) 2018-05-04 2021-05-19 Incyte Corp Sales de un inhibidor de fgfr
CN119241541A (zh) 2018-05-04 2025-01-03 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
WO2020185532A1 (fr) 2019-03-08 2020-09-17 Incyte Corporation Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (fr) 2019-10-01 2021-04-08 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021088859A1 (fr) * 2019-11-06 2021-05-14 暨南大学 Composé d'indazole, composition pharmaceutique de celui-ci et ses applications
CA3163875A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
IL293001A (en) 2019-12-04 2022-07-01 Incyte Corp Derivatives of fgfr repressors
WO2021138391A1 (fr) * 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Composés d'indazole
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2022033472A1 (fr) * 2020-08-11 2022-02-17 河南迈英诺医药科技有限公司 Composé inhibiteur de fgfr et son utilisation
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
WO2022261160A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
CN116554148B (zh) * 2022-12-13 2025-01-28 药康众拓(北京)医药科技有限公司 一种乙烯基吲唑类氘代fgfr抑制剂药物及用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
ATE386736T1 (de) 2000-09-11 2008-03-15 Novartis Vaccines & Diagnostic Verfahren zur herstellung von benzimidazol-2-yl - chinolinonderivaten
EP1447405A4 (fr) * 2001-10-17 2005-01-12 Kirin Brewery Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes
KR20050004214A (ko) * 2002-05-31 2005-01-12 에자이 가부시키가이샤 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물
DE10342503A1 (de) * 2003-09-12 2005-04-14 Merck Patent Gmbh Benzyl-Benzimidazolylderivate
BRPI0511533A (pt) 2004-05-26 2008-01-02 Pfizer derivados indazol e indolona e seu uso como medicamento
WO2007058626A1 (fr) 2005-11-16 2007-05-24 S*Bio Pte Ltd Composes d'indazole
WO2007067537A1 (fr) * 2005-12-07 2007-06-14 Osi Pharmaceuticals, Inc. Composés inhibant les pyrrolopyridine kinases
CN101594862B (zh) 2006-12-20 2015-11-25 内尔维阿诺医学科学有限公司 作为激酶抑制剂的取代吲唑衍生物
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
NZ581698A (en) 2007-06-05 2012-09-28 Merck Sharp & Dohme Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
DE102007028521A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
EP2265270A1 (fr) * 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. Inhibiteurs de 2-aminopyridine kinases

Also Published As

Publication number Publication date
CA2760535C (fr) 2014-01-14
TWI382982B (zh) 2013-01-21
AR078411A1 (es) 2011-11-09
HK1163665A1 (en) 2012-09-14
PE20120812A1 (es) 2012-07-08
BRPI1013748A2 (pt) 2016-04-05
JP2012526126A (ja) 2012-10-25
MY160390A (en) 2017-03-15
IL216004A0 (en) 2012-01-31
AU2010246114A1 (en) 2011-11-03
CR20110580A (es) 2012-01-06
KR101373910B1 (ko) 2014-03-12
ES2408117T3 (es) 2013-06-18
AU2010246114B2 (en) 2012-12-06
CN102421769B (zh) 2014-04-02
MX2011011342A (es) 2011-11-18
TW201105652A (en) 2011-02-16
JP5555314B2 (ja) 2014-07-23
SI2427449T1 (sl) 2013-05-31
CL2011002781A1 (es) 2012-05-25
CO6450624A2 (es) 2012-05-31
PT2427449E (pt) 2013-05-06
ME01462B (me) 2014-04-20
NZ595553A (en) 2013-05-31
KR20120004511A (ko) 2012-01-12
CA2760535A1 (fr) 2010-11-11
US20100286209A1 (en) 2010-11-11
PE20160124A1 (es) 2016-02-24
HRP20130323T1 (en) 2013-05-31
SG175909A1 (en) 2011-12-29
RS52795B (sr) 2013-10-31
EA201171367A1 (ru) 2012-04-30
CN102421769A (zh) 2012-04-18
EA018149B1 (ru) 2013-05-30
EP2427449A1 (fr) 2012-03-14
JO2860B1 (en) 2015-03-15
WO2010129509A1 (fr) 2010-11-11
EP2427449B1 (fr) 2013-04-03
IL216004A (en) 2014-01-30
ECSP11011441A (es) 2011-12-30
UA104756C2 (uk) 2014-03-11
DK2427449T3 (da) 2013-04-22
PL2427449T3 (pl) 2013-08-30
HN2011002809A (es) 2013-07-22
US8268869B2 (en) 2012-09-18

Similar Documents

Publication Publication Date Title
MA33244B1 (fr) Composes de vinylindazolyle
EP2482849A4 (fr) Immunothérapie combinée pour le traitement du cancer
FR2932478B1 (fr) Composes utiles pour le traitement des cancers.
EP2391316A4 (fr) Traitement de l'obésité
FR2948016B1 (fr) Orthese pour le traitement de la rhizarthrose
MX364200B (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
EP2310006A4 (fr) Traitement du cancer
ES2661055T8 (es) Determinación de haplotipos de KIR por amplificación de exones
PL3023788T3 (pl) Kompozycje neoantygenów specyficznych wobec nowotworu do zastosowania w leczeniu nowotworów
EP2493820A4 (fr) Traitement de l'eau
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
EP2496244A4 (fr) Immunothérapie pharmacorésistante pour le traitement d'un cancer
EP1996612A4 (fr) Compositions destinee au traitement des cancers
EP2498796A4 (fr) Traitement d'une cardiopathie
PH12012501542A1 (en) Treatment of inflammatory bowel diseases with mammal beta defensis
PH12012501680A1 (en) Compositions and methods for the diagnosis and treatment of tumor
MA32617B1 (fr) Traitement de l'hypertension arterielle pulmonaire
EP2382329A4 (fr) Utilisations de bortézomib pour prédire la survie de patients atteints d'un myélome multiple
IN2012DN00539A (fr)
MY151104A (en) Novel use
EP2517095A4 (fr) Traitement de recouvrements
EP2608671A4 (fr) Composés utilisés dans le traitement du cancer
EP2582391A4 (fr) Traitement de l'arthrite
EP2274245A4 (fr) Phytosystème destiné au traitement des eaux usées
IN2015DN00515A (fr)